Chugai Pharmaceutical Co., Ltd.
4519
Rank in Stocks
#346
Chugai Pharmaceutical Co., Ltd. is a prominent global pharmaceutical company,... Chugai Pharmaceutical Co., Ltd. is a prominent global pharmaceutical company, operating subsidiaries involved in the full lifecycle of drug development, from research and manufacturing to sales, import, and export, serving both Japanese and international markets. Its commercialized product portfolio spans several key therapeutic areas. These include a robust oncology offering with leading treatments like Avastin, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, Gazyva, and Xeloda. Additionally, it provides medications for bone health (e.g., Actemra, Edirol, Bonviva), renal conditions (such as Mircera and Oxarol), and neurological or other diverse ailments (including Hemlibra, CellCept, and Enspryng). Beyond its existing offerings, the company maintains an active research and development pipeline. This pipeline features multiple promising candidates targeting oncology, orthopedic and joint disorders, autoimmune diseases, kidney-related conditions, and various neurological or other health issues. Strategic partnerships are central to Chugai's operations, most notably a significant alliance with the Roche Group. The company also fosters collaborative research initiatives with academic institutions. Established in 1925, Chugai's headquarters are located in Tokyo, Japan, and it operates as a key subsidiary of Roche Holding Ltd.
Share Price
$42.53
Market Cap
$69.98B
Change (1 day)
1.37%
Change (1 year)
-14.40%
Country
JP
Trade Chugai Pharmaceutical Co., Ltd. (4519)
Category
Healthcare
Stock price history for Chugai Pharmaceutical Co., Ltd. (4519)
Highest end of day price: $38.86 on 2026-10-01
Lowest end of day price: $51.75 on 2000-11-01
Lowest end of day price: $51.75 on 2000-11-01
Stock price history of Chugai Pharmaceutical Co., Ltd. from 2000 to 2026
Annual Stock Price Performance
| Year | Performance |
|---|---|
| 2026 (TTM) | -7.35% |
| 2025 | 24.85% |
| 2024 | 17.22% |
| 2023 | 54.46% |
| 2022 | -26.90% |
| 2021 | -29.65% |
| 2020 | 549.58% |
| 2019 | -29.61% |
| 2018 | 118.94% |
| 2017 | 21.69% |
| 2016 | -66.07% |
| 2015 | 245.37% |
| 2014 | 26.29% |
| 2013 | -97.98% |
| 2012 | 161.03% |
| 2011 | -12.65% |
| 2010 | -8.22% |
| 2009 | 13.93% |
| 2008 | 6.97% |
| 2007 | -20.27% |
| 2006 | -7.51% |
| 2005 | 47.49% |
| 2004 | 2.63% |
| 2003 | 84.70% |
| 2002 | -39.16% |
| 2001 | -23.39% |
| 2000 | 0.00% |
Stock price for similar companies or competitors
| Company | Stock price | Change 1y% | Country |
|---|---|---|---|
| $1.27K | 59.16% |
US
|
|
| $257.61 | 34.26% |
US
|
|
| $284.48 | 22.94% |
US
|
|
| $149.84 | 71.01% |
US
|
|
| $482.98 | 31.13% |
CH
|
